KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice

KaloBios Pharma (KBIO) Could Drop 50% By Early Next Week: Tim Sykes

Tim Sykes thinks KaloBios Pharma (NASDAQ: KBIO) could drop 50% by early next week, according to the New York... More

KaloBios Pharma's (KBIO) Delisting Notification Comes as No Surprise

KaloBios Pharma (Nasdaq: KBIO) shares are down around 9 percent following news that it received a delisting notice from the Nasdaq Stock Market. The notification comes following a sharp run higher as Martin Shkreli made a major investment in the company and was subsequently appointed as its CEO.

But, the delisting notification shouldn't come as a surprise to anyone following the stock. The company filed an... More

KaloBios Pharma (KBIO) CEO Shkreli Purchased 5,000 Shares

KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli disclosed a recent stock purchase.

In a Form 4 filing made today, Shkreli purchased 5,000 shares of the company's stock on November 20th for $18.88 per share.

The filing is embedded below:

Unusual 11 Mid-Day Movers 11/23: (KBIO) (EFUT) (NBG) Higher; (ARP) (PCO) (PRQR) Lower

KaloBios Pharma (Nasdaq: KBIO) 105.5% HIGHER; gaining once again as volatility in the name continues. The company named Martin Shkreli as CEO last week following a large investment.

eFuture Information Technology Inc. (Nasdaq: EFUT) 59.0% HIGHER; reported Q3 net loss of RMB3.9 million (US$0.6 million), compared to a net loss of RMB 1.8 million in the third quarter 2014. Third quarter total revenue increased 6% year-over-year to RMB36.1 million.

National Bank of Greece (NYSE: NBG) 42.5%... More

Shkreli Rubs Salt in KaloBios Pharma (KBIO) Short Sellers' Wounds

KaloBios Pharma (NASDAQ: KBIO) new CEO Martin Shkreli just tweeted a picture of himself and others at the company's headquarters captioned "turnaround in progress."

Shares have surged from $0.90 to over $45 in a few days amid news a Shkreli group has accumulated... More

Cleveland Biolabs (CBLI) Sees Mid-Day Upside on KBIO Comparison

Cleveland Biolabs (NASDAQ: CBLI) bumps higher mid-day as company is compared to KaloBios Pharma (NASDAQ: KBIO).

KaloBios Pharma (KBIO) Halted Again on LUDP

KaloBios Pharma (NASDAQ: KBIO) is again halted on limit-up, limit-down trading pause. Last up 109.32%

KaloBios Pharma (KBIO) triggers limit-up, limit-down trading pause

KaloBios Pharma (NASDAQ: KBIO) triggers limit-up, limit-down trading pause.

UPDATE - Shares are now above $45 and are up over 150 percent on today's session. The move is staggering when considering that KBIO closed at $.90 as recently as November 13th.

KaloBios Pharmaceuticals (KBIO) Squeezes Toward $30/Share

KaloBios Pharmaceuticals (NASDAQ: KBIO) is pushing toward $30 as shorts are squeezed with a very limited float. The stock was just $0.90 on Nov 13.

Pre-Open Stock Movers 11/23: (CANF) (KBIO) (MNK) Higher; (PARR) (CAVM) (AGN) Lower (more...)

Can-Fite BioPharma (NYSE: CANF) 37.6% HIGHER; announced development of its drug candidate CF102, which is currently in Phase II trials for hepatocellular carcinoma (HCC) the most common form of liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis (NASH).

KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) 24.3% HIGHER; continues higher on short squeeze.

Novocure... More

KaloBios Pharma (KBIO) Continues Run-Up on Epic Short Squeeze

KaloBios Pharma (NASDAQ: KBIO) is continuing higher pre-open Monday as the epic short... More

Top 10 News for 11/16 - 11/20: Airgas (ARG) Gets Acquisition Offer; Shkreli Named KaloBios CEO; UnitedHealth Hit on Outlook

1. Tuesday, Air Liquide and Airgas (NYSE: ARG) announced an agreement under which Air Liquide will acquire Airgas. Airgas shareholders will receive $143 per share in cash for all outstanding shares of Airgas, representing a total enterprise value of $13.4 billion (12.5 billion at current exchange rates1) on a fully diluted basis and including the assumption of Airgas debt.

2. KaloBios Pharma (Nasdaq: KBIO) was... More

Unusual 11 Mid-Day Movers 11/20: (KBIO) (MCUR) (SRPT) Higher; (NMBL) (APTO) (MENT) Lower

KaloBios Pharma (Nasdaq: KBIO) 81.3% HIGHER; announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David Moradi, Tony Chase and Marek Biestek have been elected to the... More

Macrocure (MCUR) Ramps Higher

Macrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.

KaloBios Pharma (KBIO) Resumes Trading, Holds Gains

KaloBios Pharma (NASDAQ: KBIO) resumes trading. Shares are up over 85 percent, but pulling back from earlier highs.

KaloBios Pharma (KBIO) triggers anther limit-up, limit-down trading pause

KaloBios Pharma (NASDAQ: KBIO) triggers limit-up, limit-down trading pause.

KaloBios Pharma (KBIO) Halted on LUDP

KaloBios Pharma (NASDAQ: KBIO) Halted on LUDP

Pre-Open Stock Movers 11/20: (KBIO) (SRPT) (ANF) Higher; (NMBL) (MENT) (BMRN) Lower (more...)

Nimble Storage (NYSE: NMBL) 46.1% LOWER; reported Q3 EPS of ($0.14), $0.06 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $80.7 million versus the consensus estimate of $87.44 million. Nimble Storage sees Q4 2015 EPS of ($0.11)-($0.13), versus the consensus of $0.00. Nimble Storage sees Q4 2015 revenue of $87-90 million, versus the consensus of $99.20 million. Multiple... More

Newly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment

Incoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday... More

KaloBios Pharma (KBIO) Names Martin Shkreli as CEO

KaloBios Pharma (NASDAQ: KBIO) announced that an investor group led by Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares. KaloBios also announced the appointment of Martin Shkreli to the position of Chief Executive Officer and his election as Chairman of the Board. In his new role, Mr. Shkreli will work with the company's senior management team to ensure the Company's continued operations. KaloBios further announced that David... More

Needham & Company Drops Coverage of KaloBios Pharma (KBIO)

Needham & Company dropped coverage of KaloBios Pharma (NASDAQ: KBIO).

Analyst Alan Carr commented, "Kalobios announced last week plans to wind down operations and liquidate company assets. Management had expressed concern at the time that it was unlikely efforts to explore strategic... More

Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street

The stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.

$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.

You see, just... More

Unusual 11 Mid-Day Movers 11/19: (KBIO) (ICLD) (GMCR) Higher; (KIRK) (BONT) (GEOS) Lower

KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) 336.9% HIGHER; announced that it has been informed that an investor group comprised of Martin Shkreli and associates together have acquired more than 50% of the outstanding shares of KaloBios, and that the company is in discussions with Mr. Shkreli regarding possible direction for the company to continue in operation. Mr. Shkreli is the founder and chief executive officer of Turing Pharmaceuticals, a privately held biopharmaceutical company.

InterCloud Systems (Nasdaq: ICLD) 26.6% HIGHER; announced that it was recently... More